mGlu2 Receptors in the Basal Ganglia: A New Frontier in Addiction Therapy
Frontiers in Bioscience-Landmark · 2025
DOI: 10.31083/fbl26637 ↗At a glance
Übersichtsarbeit in Frontiers in Bioscience-Landmark, 2025. Written by Li-Min Mao and 2 co-authors. Institution: Department of Biomedical Sciences, University of Missouri-Kansas City, School of Medicine, Kansas City, MO 64108, USA. Major MEDLINE topics: Receptors, Metabotropic Glutamate, Basal Ganglia, Substance-Related Disorders. Cited 3 times so far (Crossref); 152 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIMH NIH HHS, NIH HHS, NIH.
Topics: Sucht und Abhängigkeit
Abstract (original language)
Glutamate is an important neurotransmitter in the mammalian brain. Among the receptors that glutamate interacts with is metabotropic glutamate (mGlu) receptor 2, a Gαi/o-coupled receptor. These receptors are primarily located on glutamatergic nerve terminals and act as presynaptic autoreceptors to produce feedback inhibition of glutamate release. Abundant mGlu2 receptors are distributed in major glutamatergic pathways in the basal ganglia, especially the corticostriatal and thalamostriatal projections in the striatum. These receptors are involved in the regulation of motivation, reward processing, learning, motor, and cognitive functions. As an inhibitory presynaptic receptor, mGlu2 is linked to the addictive properties of drugs of abuse, a topic summarized in this review. Chronic exposure to multiple addictive drugs and alcohol causes the adaptive downregulation of mGlu2 receptors in their expression and function in the key regions of the limbic reward circuit. This downregulation contributes to the remodeling of limbic excitatory synaptic transmission and plasticity critical for enduring drug-seeking behavior. Normalization of mGlu2 activity by pharmacological or genetic approaches attenuates drug taking and seeking. Here, we highlight that recent progress in mGlu2 biology research demonstrates the pivotal roles of mGlu2 receptors in different aspects of drug addiction. mGlu2 subtype-selective agents (both orthosteric and allosteric compounds) thus have the potential to be developed into novel pharmacotherapies for addictive conditions.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biomedical Sciences, University of Missouri-Kansas City, School of Medicine, Kansas City, MO 64108, USA.
- Department of Anesthesiology, University of Missouri-Kansas City, School of Medicine, Kansas City, MO 64108, USA.
Funding
- NIMH NIH HHS
- NIH HHS
- NIH
Cite
APA
Mao, L. M., Puthumana, E., & Wang, J. Q. (2025). mGlu2 Receptors in the Basal Ganglia: A New Frontier in Addiction Therapy. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl26637
Vancouver
Mao LM, Puthumana E, Wang JQ. mGlu2 Receptors in the Basal Ganglia: A New Frontier in Addiction Therapy. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl26637
BibTeX
@article{Mao2025,
author = {Mao, Li-Min and Puthumana, Elizabeth and Wang, John Q},
title = {mGlu2 Receptors in the Basal Ganglia: A New Frontier in Addiction Therapy},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
doi = {10.31083/fbl26637}
}
EUVIMED